PATENT CLAIM ANALYSIS

Application Number: 16126892
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["514", "363000"]

Abstract:
Methods are disclosed herein for administering a oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitor for treating autoimmune and/or glomerulonephritis-associated diseases, and in particular, Systemic Lupus Erythematosus (SLE).

Claim (Index 4):
The method of  claim 1  wherein the SHP2 inhibitor is administered in an amount ranging from about 1 mg/Kg body weight/day to about 25 mg/Kg body weight/day.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 97.0
- Lexical Diversity: 1.12121
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15813729', '14902485', '14786621', '15577417', '15577398']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.770133044533343
- 35 USC 102 Novelty (BERT): 0.7138621739990161
- Combined Prediction Score: 0.7645059574799102
- Mean Citation Score: 456.1451139999999
- Max Citation Score: 748.03815
- Similarity Product: 739.0584191906693

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test